Expansion of inpatient clinical pharmacy services through reallocation of pharmacists.

Purpose: The redesign of an inpatient pharmacy practice model through reallocation of pharmacy resources in order to expand clinical services is described.

Methods: A pharmacy practice model change was implemented at a nonprofit academic medical center to meet the increasing demand for direct patient care services. In order to accomplish this change, the following steps were completed: reevaluation of daily tasks and responsibilities, reallocation of remaining tasks to the most appropriate pharmacy staff member, determination of the ideal number of positions needed to complete each task, and reorganization of the model into a collection of teams.

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.

Purpose: Bortezomib (PS-341), a first-in-class proteasome inhibitor, is metabolized by deboronation involving cytochrome P4503A (CYP3A), which also metabolizes docetaxel. Preclinical studies have shown synergy between bortezomib and taxanes. We conducted a phase I study combining bortezomib and docetaxel in refractory solid tumor patients.